The US affiliate of specialty pharmaceutical company Indivior has launched an authorised generic version of Suboxone (buprenorphine and naloxone) sublingual film, a prescription medicine developed to treat of opioid dependence, in the United States, it was reported yesterday.
Sandoz will market the authorised generic version of Suboxone on behalf of Indivior in the US.
Indivior stated that its decision is based on the market impact expected from the anticipated at risk launch of a generic buprenorphine film product in the US by Dr Reddy's Laboratories and Alvogen Pine Brook.
On 19 February, the US Supreme Court rejected Indivior's motion to stay issuance of the mandate vacating the preliminary injunction (PI) granted against Dr Reddy's. Later, the US District Court for the District of New Jersey passed orders to dissolve the temporary restraining order against Alvogen and confirming the PI against Dr Reddy's had been vacated.
The court decision allows Dr Reddy's and Alvogen to sell or import their generic buprenorphine/naloxone sublingual film products.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling